Neratinib, a Clinical Drug Treating Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis
Taken together, these findings support the concept that neratinib could be tested as a repurposed drug for vascular inflammation and atherosclerosis, thereby streamlining efforts to translate preclinical discoveries to clinical testing in humans.
Authors
- S. Xu
- He Cy
- Fan-shun Zhang
- Jiang-Yun Luo
- Xiumei Wu
- Danielle Kamato
- Ruixue Leng
- Jianping Weng
Institutions
- Griffith University (AU)
- University of Science and Technology of China (CN)
- Bengbu Medical College (CN)
- Anhui Medical University (CN)
- Hefei Institutes of Physical Science (CN)
- Anhui Provincial Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Circulation Research
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1161/circresaha.125.326508
- Primary Topic
- Kruppel-like factors research
- Type
- article
- Field-Weighted Citation Impact
- 0.00